drugset / Trial / NCT00671307

Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels

NCT00671307 ↗

Phase 1/2 Completed 40 enrolled Critical Biologics Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to assess the pharmacokinetics and safety of an infusion of a single dose of recombinant plasma gelsolin (rhu-pGelsolin) when given to patients admitted to the Intensive Care Unit with documented low levels of natural gelsolin. It is believed that this drug will raise the gelsolin levels in these patients and decrease the probability that they will develop complications from their underlying disease such as organ system failure or death.

Timeline

Start
2008-03
Primary completion
2010-03
Completion
2010-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject rhu-pGelsolin Protein / enzyme biologic 3 mg/kg Intravenous
Subject rhu-pGelsolin Protein / enzyme biologic 6 mg/kg Intravenous